Fig. 5: Efficacy of cleavable chimeric peptide R7 in the mice challenged with MDR E. coli. | Communications Biology

Fig. 5: Efficacy of cleavable chimeric peptide R7 in the mice challenged with MDR E. coli.

From: A cleavable chimeric peptide with targeting and killing domains enhances LPS neutralization and antibacterial properties against multi-drug resistant E. coli

Fig. 5

a Survival of mice. Mice were intraperitoneally injected with 7 μmol/kg different peptides (including R7, L7, LBP14-RKRR, the ‘LBP14-RKRR + L7’ combination) at 0 h (five mice/group), followed by injection with MDR E. coli CVCC195 (0.5 × 109 CFU/mouse) at 6 h. Survival was recorded for 7 days. Two biological replicates were done. b Effects of peptides on the bacterial counts in lungs. Mice were infected intraperitoneally with MDR E. coli CVCC195 (0.5 × 109 CFU/mouse) and pre-treated with 7 μmol/kg different peptides at 6 h (three mice/group) before infection, respectively. Lungs were removed at 12 h and 24 h after infection to analyze bacterial translocation. c–g Effects of peptides on cytokines (c–f) and the IAP levels in mice (g). The results are given as the mean ± SD of three independent experiments. Different lower-case letters indicate a significant difference between the two groups (p < 0.05).

Back to article page